Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on SCAPA GROUP PLC. We currently have 34 research reports from 2 professional analysts.
|23Mar17 11:46||RNS||Additional Listing|
|01Mar17 10:22||RNS||Additional Listing|
|23Feb17 11:03||RNS||Holding(s) in Company|
|16Feb17 09:21||RNS||Holding(s) in Company|
|07Feb17 16:16||RNS||Block listing Interim Review|
|03Feb17 15:53||RNS||Holding(s) in Company|
|26Jan17 10:10||RNS||Director/PDMR Shareholding|
Frequency of research reports
Research reports on
SCAPA GROUP PLC
SCAPA GROUP PLC
N+1 Singer - Scapa Group - From strength to strength
22 Nov 16
The first half was positive; we upgraded in October and are upgrading again this morning driven primarily by efficiency gains in the Industrial division. Forecast EPS in FY17 rises by 11% and in FY18 by 7%. The efficiency driven margin improvement in Industrials is spectacular (from 6.7% to 9.3%) with more to come as Rorschach closes. The Healthcare pipeline is also strong and Euromed is integrating well. With ongoing strong momentum, we increase our target price in line with the upgrades to 333p; we remain at Buy.
N+1 Singer - Morning Song 22-11-2016
22 Nov 16
Cambria Automobiles (CAMB LN) Another strong year and delivery of strategy | Carador Income Fund (CIFU LN) Total return up 1.7% in October, inclusive of 2.25c Q3 dividend | Scapa Group (SCPA LN) From strength to strength | Vectura Group (VEC LN) Development agreement with Hikma
Interims – Strong underlying progress & FX tailwinds
22 Nov 16
Scapa has made great strides in improving the quality of the business both from growing the Healthcare division (currently around 50% of divisional operating profits before central costs) and from the improving quality of earnings in Industrial. We believe that there is further scope on this front, particularly with the benefits from the closure of Rorschach, which should take Industrial margins towards 10%. The legacy pension funding issue also continues to be carefully managed, with a stable funding structure. The full PER rating recognises the strength of the record and the current business, but continued successful delivery of the Group’s strategy should deliver further significant shareholder value, and there is further scope to enhance earnings via acquisition. We maintain our Add recommendation.
N+1 Singer - Scapa Group - Trading well; currency and efficiency gains lead to upgrades
12 Oct 16
The brief update is confident in tone and reflects our expectation of currency upgrade potential within our industrial research population as noted in our sector report of 9th September. We have upgraded FY17 EPS by 4.3% and FY18 by 5.5%, primarily reflecting this currency benefit, as well as efficiency gains. Encouragingly, trading trends seem to be unchanged and the Euromed acquisition is said to be integrating well. With ongoing strong momentum and an increasing currency tailwind, we increase our price target to 309p (c.14.5x EV/EBITDA) and remain at Buy.
N+1 Singer - Morning Song 12-10-2016
12 Oct 16
Bodycote (BOY LN) New FD announced | Domino’s Pizza UK & IRL (DOM LN) Better than feared Q3 update | Marston’s (MARS LN) Solid YE trading update | Midatech Pharma (MTPH LN) Pivotal year ahead post successful capital raise | PROACTIS Holdings (PHD LN) Strong underlying growth in recurring revenue | Scapa Group (SCPA LN) Trading well; currency and efficiency gains lead to upgrades | Synairgen (SNG LN) AZD9412 clinical trial update | Vertu Motors (VTU LN) Positive trading in H1 and Sept and outlook for A/S and Used | Walker Greenbank (WGB LN) Complementary acquisition bolsters growth outlook, c25% upgrades
H1 Update - “confident of strong progress for the year”
12 Oct 16
Scapa is a worldwide leading supplier of bonding solutions and adhesive components with manufacturing and sales operations in eleven countries across North America (sales: £129m), Europe (£102m) and Asia (£14m). The business now operates as two divisions: Industrial (£153m sales; £11m profits) and Healthcare (£93m sales; £14m profits).
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.
19 Dec 16
600 GROUP | ACCSYS TECHNOLOGIES | AGGREGATED MICRO POWER HLDGS PLC | ALUMASC GROUP | ANGLO-EASTERN PLANTATIONS | AVINGTRANS PLC | CAPITAL DRILLING LTD | CARCLO | FENNER PLC | FLOWTECH FLUIDPOWER PLC | GLOBAL INVACOM GROUP LTD | GOOCH & HOUSEGO PLC | HARDIDE PLC | HAYWARD TYLER GROUP PLC | IOFINA PLC | M.P.EVANS GROUP | R.E.A. HLDGS PLC | REDT ENERGY PLC | RENOLD | ROBINSON | SOMERO ENTERPRISE INC | SURFACE TRANSFORMS PLC | TRANSENSE TECHNOLOGIES PLC | TRIFAST | ZAMBEEF PRODUCTS
14 Mar 17
Zotefoams finals present a mixed picture. After a slow first half, when revenues grew 2%, stronger growth in H2 left overall revenues up 7% to £57.4m, helped by a strong FX tailwind. On a constant FX basis, revenues were 3% lower, with declines in Polyolefin foams and MuCell more than offsetting growth in HPP.